Study finds emodepside formulations aren’t interchangeable in dogs

Version 1

A new American Journal of Veterinary Research study is sharpening the conversation around extra-label emodepside use in dogs with multi-anthelmintic drug-resistant hookworms: the FDA-approved feline topical formulation and the EMA-approved canine oral tablet are not bioequivalent when given orally to dogs. In the crossover pharmacokinetic study, seven dogs received emodepside as an oral dose of the feline topical solution, the canine modified-release tablet, and the feline topical solution applied topically. Researchers found that oral administration of the feline topical product produced markedly higher absorption than the canine tablet, with peak plasma concentrations about 3 times higher and overall systemic exposure about 2.4 to 2.8 times greater; topical administration produced plasma concentrations 36- to 122-fold lower than oral dosing. In the U.S., emodepside is approved as Profender topical solution for cats, not for dogs, which makes these findings especially relevant for clinicians managing resistant hookworm cases with limited options. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the takeaway is simple: formulation matters, and substituting one emodepside product for another can materially change exposure and risk. Emodepside is also notable because it belongs to the octadepsipeptide class, with a mechanism distinct from other marketed anthelmintic drug classes, which helps explain why it has drawn interest in resistant hookworm cases. The study raises safety concerns around extra-label oral use of the feline topical product in dogs, echoing prior expert guidance that recommends careful case selection, heartworm screening, MDR1 consideration where appropriate, informed consent, and close in-hospital monitoring if emodepside is used at all. Resistant hookworms remain a growing clinical and public health concern, but this paper suggests clinicians should be cautious about assuming that an oral dose made from a topical cat product will behave like a canine oral formulation used outside the U.S. (pubmed.ncbi.nlm.nih.gov)

What to watch: Expect more discussion around standardized protocols, safety monitoring, and whether additional efficacy and dosing studies can better define when, and how, emodepside should be used in dogs with resistant hookworm infections. The new data also reinforce a basic pharmacology point likely to shape that discussion: route and formulation are not interchangeable, even at the same mg/kg dose. (pubmed.ncbi.nlm.nih.gov)